<DOC>
	<DOCNO>NCT00718640</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety bortezomib participant previously treat multiple myeloma ( cancer plasma cell bone marrow cause numerous tumor characterize presence abnormal protein blood ) limit kidney function .</brief_summary>
	<brief_title>An Efficacy Safety Study Bortezomib Participants Previously Treated Multiple Myeloma With Limited Kidney Function</brief_title>
	<detailed_description>This open label ( people know identity intervention ) , multi-center ( study conduct multiple site ) , non-comparative , single arm study bortezomib . The study consist 3 phase : Screening phase ( 21 day Day 1 cycle 1 ) ; Treatment phase ( consist 8 cycle cycle 21 day disease progression unacceptable toxicity ) ; Follow-up phase ( participant positive treatment response stable disease final visit ) . Follow-up disease progression do every 3 month 2 year . Participants experience disease progression complete least 2 cycle bortezomib treatment change baseline stable disease complete least 4 cycle per Investigator 's discretion receive dexamethasone . Efficacy primarily evaluate percentage participant renal compromised Multiple Myeloma International Myeloma Working Group ( IMWG ) uniform response criterion . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Participants diagnose symptomatic multiple myeloma base International Myeloma Working Group ( IMWG ) criterion ; great equal 10 percent plasma cell bone marrow ( tissue biopsy ) detect , monoclonal protein serum urine , presence endorgan injury Participants measurable disease define least 1 follow 5 measurement : ) serum Mprotein great equal 1 gram per deciliter ( g/dl ) , b ) Urine M Protein great equal 200 milligram per 24 hour , c ) Serum free light chain ( FLC ) assay : Involved FLC level great 10 mg per dl ( mg/dl ) provide serum FLC ratio abnormal , ) Bone marrow plasma cell great equal 30 percent Participants receive least 1 prior line chemotherapy multiple myeloma , refractory relapse last therapy Participants Karnofsky performance status great 60 Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Participants calculate measured creatinine clearance less equal 30 mililiter per minute ( ml/min ) . During screen period , 2 measure creatinine clearance least 7 day apart must obtain , must less 30 ml/min Participants receive bortezomib previous clinical trial best response progressive disease experience one serious event Participants receive nitorsoureas within 6 week , 2 consecutive week intense corticosteroid , immunotherapy antibody therapy within 4 week enrolment Participants history allergic reaction attributable compound contain boron mannitol Participants peripheral neuropathy Grade 2 great intensity time sign informed consent form Pregnant breastfeed female participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Velcade</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>